Incyte Corp
INCY
View Detailed Chart
92.260USD
+0.030+0.03%
Close 03/26, 16:00（ET）Quotes delayed by 15 min
11.81BMarket Cap
14.00P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.03%
5 Days
-0.74%
1 Month
-7.82%
6 Months
+11.56%
Year to Date
-6.59%
1 Year
+50.60%
View Detailed Chart
TradingKey Stock Score of Incyte Corp
Currency: USD Updated: 2026-03-25Key Insights
Incyte Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 107.67.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Incyte Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Incyte Corp Highlights
StrengthsRisks
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 39.12% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.14B.
Undervalued
The company’s latest PE is 13.99, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 207.27M shares, decreasing 0.83% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 34.30K shares of this stock.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
107.674
Target Price
+19.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Incyte Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Incyte Corp Info
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Ticker SymbolINCY
CompanyIncyte Corp
CEOMeury (Bill)
Websitehttps://www.incyte.com/
Related Instruments
-2.11%
-1.00%
-0.29%
-2.00%
-0.37%
+1.90%
-0.70%
-0.22%
-1.84%
+1.06%
+0.19%
+1.28%
-1.39%
+0.83%
-0.27%
0.00%
+0.97%
-1.71%
-0.07%
-1.26%Popular Symbols
252.890
+0.270 (+0.11%)
171.240
-7.440 (-4.16%)
68910.000
-65.210 (-0.10%)
273.350
-22.790 (-7.70%)
2064.120
+1.730 (+0.08%)
372.110
-13.840 (-3.59%)
4403.690
+23.630 (+0.54%)
92.369
-0.953 (-1.02%)
1.153
+0.001 (+0.06%)
159.693
-0.094 (-0.06%)
